Acute and Critical Care

Original Article

Pulmonary
Effect of Renin-Angiotensin System Blockage in Patients with Acute Respiratory Distress Syndrome: A Retrospective Case Control Study: Joohae Kim, Sun Mi Choi, Jinwoo Lee, Young Sik Park, Chang Hoon Lee, Jae-Joon Yim, Chul-Gyu Yoo, Young Whan Kim, Sung Koo Han, Sang-Min Lee; Korean J Crit Care Med. 2017;32(2):154-163. Published online May 31, 2017; DOI: https://doi.org/10.4266/kjccm.2016.00976

11,146 View
185 Download
29 Web of Science
32 Crossref

Background
Acute respiratory distress syndrome (ARDS) remains a life-threatening disease. Many patients with ARDS do not recover fully, and progress to terminal lung fibrosis. Angiotensin-converting enzyme (ACE) inhibitor is known to modulate the neurohormonal system to reduce inflammation and to prevent tissue fibrosis. However, the role of ACE inhibitor in the lungs is not well understood. We therefore conducted this study to elucidate the effect of renin-angiotensin system (RAS) blockage on the prognosis of patients with ARDS.
Methods
We analyzed medical records of patients who were admitted to the medical intensive care unit (ICU) at a tertiary care hospital from January 2005 to December 2010. ARDS was determined using the Berlin definition. The primary outcome was the mortality rate of ICU. Survival analysis was performed after adjustment using propensity score matching.
Results
A total of 182 patients were included in the study. Thirty-seven patients (20.3%) took ACE inhibitor or angiotensin receptor blocker (ARB) during ICU admission, and 145 (79.7%) did not; both groups showed similar severity scores. In the ICU, mortality was 45.9% in the RAS inhibitor group and 58.6% in the non-RAS inhibitor group (P = 0.166). The RAS inhibitor group required a longer duration of mechanical ventilation (29.5 vs. 19.5, P = 0.013) and longer ICU stay (32.1 vs. 20.2 days, P < 0.001). In survival analysis, the RAS inhibitor group showed better survival rates than the non-RAS group (P < 0.001).
Conclusions
ACE inhibitor or ARB may have beneficial effect on ARDS patients.

Citations

Citations to this article as recorded by

Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19
Nancy Xurui Huang, Qi Yuan, Fang Fang, Bryan P. Yan, John E. Sanderson, Masaki Mogi
PLOS ONE.2023; 18(1): e0280280. CrossRef
Renin-angiotensin system modulators in COVID-19 patients with hypertension: friend or foe?
Shakhi Shylesh C.M, Arya V S, Kanthlal S. K., Uma Devi P.
Clinical and Experimental Hypertension.2022; 44(1): 1. CrossRef
A propensity score‐matching analysis of angiotensin‐converting enzyme inhibitor and angiotensin receptor blocker exposure on in‐hospital mortality in patients with acute respiratory failure
Yi‐Peng Fang, Xin Zhang
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.2022; 42(5): 387. CrossRef
The Renin-Angiotensin System as a Component of Biotrauma in Acute Respiratory Distress Syndrome
Katharina Krenn, Verena Tretter, Felix Kraft, Roman Ullrich
Frontiers in Physiology.2022;[Epub] CrossRef
ACE2-like enzyme B38-CAP suppresses abdominal sepsis and severe acute lung injury
Takafumi Minato, Tomokazu Yamaguchi, Midori Hoshizaki, Satoru Nirasawa, Jianbo An, Saori Takahashi, Josef M. Penninger, Yumiko Imai, Keiji Kuba, Yu Ru Kou
PLOS ONE.2022; 17(7): e0270920. CrossRef
Tidal Volume–Dependent Activation of the Renin-Angiotensin System in Experimental Ventilator-Induced Lung Injury*
Xinjun Mao, Katharina Krenn, Thomas Tripp, Verena Tretter, Roman Reindl-Schwaighofer, Felix Kraft, Bruno K. Podesser, Yi Zhu, Marko Poglitsch, Oliver Domenig, Dietmar Abraham, Roman Ullrich
Critical Care Medicine.2022; 50(9): e696. CrossRef
The Association of Renin-Angiotensin System Blockades and Mortality in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Acute Respiratory Failure: A Retrospective Cohort Study
Zhishen Ruan, Dan Li, Yuanlong Hu, Zhanjun Qiu, Xianhai Chen
International Journal of Chronic Obstructive Pulmonary Disease.2022; Volume 17: 2001. CrossRef
Renin-angiotensin system at the interface of COVID-19 infection
Rukhsana Gul, Uh-Hyun Kim, Assim A. Alfadda
European Journal of Pharmacology.2021; 890: 173656. CrossRef
A pharmacological framework for integrating treating the host, drug repurposing and the damage response framework in COVID‐19
Jennifer H. Martin, Richard Head
British Journal of Clinical Pharmacology.2021; 87(3): 875. CrossRef
A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor
Murat Oz, Dietrich Ernst Lorke, Nadine Kabbani
Pharmacology & Therapeutics.2021; 221: 107750. CrossRef
Renin-angiotensin system blocker and outcomes of COVID-19: a systematic review and meta-analysis
Hyun Woo Lee, Chang-Hwan Yoon, Eun Jin Jang, Chang-Hoon Lee
Thorax.2021; 76(5): 479. CrossRef
Evaluation of expression of VDR-associated lncRNAs in COVID-19 patients
Mohammad Taheri, Lina Moallemi Rad, Bashdar Mahmud Hussen, Fwad Nicknafs, Arezou Sayad, Soudeh Ghafouri-Fard
BMC Infectious Diseases.2021;[Epub] CrossRef
Mechanisms of Damage to the Cardiovascular System in COVID-19
Alexandr Y. Fisun, Yuriy V. Lobzin, Dmitry V. Cherkashin, Vadim V. Tyrenko, Konstantin N. Tkachenko, Vasilii A. Kachnov, Gennadiy G. Kutelev, Ignat V. Rudchenko, Alexey D. Sobolev
Annals of the Russian academy of medical sciences.2021; 76(3): 287. CrossRef
Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers
Chirag Bavishi, Thomas M. Maddox, Franz H. Messerli
JAMA Cardiology.2020; 5(7): 745. CrossRef
COVID-19, ACE2, and the cardiovascular consequences
Andrew M. South, Debra I. Diz, Mark C. Chappell
American Journal of Physiology-Heart and Circulatory Physiology.2020; 318(5): H1084. CrossRef
Understanding the renin–angiotensin–aldosterone–SARS-CoV axis: a comprehensive review
Nicholas E. Ingraham, Abdo G. Barakat, Ronald Reilkoff, Tamara Bezdicek, Timothy Schacker, Jeffrey G. Chipman, Christopher J. Tignanelli, Michael A. Puskarich
European Respiratory Journal.2020; 56(1): 2000912. CrossRef
Putative contributions of circadian clock and sleep in the context of SARS-CoV-2 infection
Miguel Meira e Cruz, Masaaki Miyazawa, David Gozal
European Respiratory Journal.2020; 55(6): 2001023. CrossRef
COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis?
Massimo Imazio, Karin Klingel, Ingrid Kindermann, Antonio Brucato, Francesco Giuseppe De Rosa, Yehuda Adler, Gaetano Maria De Ferrari
Heart.2020; 106(15): 1127. CrossRef
Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections
Jose Manuel Quesada-Gomez, Marta Entrenas-Castillo, Roger Bouillon
The Journal of Steroid Biochemistry and Molecular Biology.2020; 202: 105719. CrossRef
Bloqueantes del sistema renina-angiotensina e infección por COVID-19
L.M. Ruilope, J.A. Garcia Donaire, A. de la Sierra
Hipertensión y Riesgo Vascular.2020; 37(3): 99. CrossRef
COVID-19: The Influence of ACE Genotype and ACE-I and ARBs on the Course of SARS-CoV-2 Infection in Elderly Patients

Jerzy Sieńko, Maciej Kotowski, Anna Bogacz, Kacper Lechowicz, Sylwester Drożdżal, Jakub Rosik, Marek Sietnicki, Magdalena Sieńko, Katarzyna Kotfis
Clinical Interventions in Aging.2020; Volume 15: 1231. CrossRef
A dissection of SARS‑CoV2 with clinical implications (Review)
Felician Stancioiu, Georgios Papadakis, Stelios Kteniadakis, Boris Izotov, Michael Coleman, Demetrios Spandidos, Aristidis Tsatsakis
International Journal of Molecular Medicine.2020; 46(2): 489. CrossRef
Outcomes Associated with the Use of Renin-Angiotensin-Aldosterone System Blockade in Hospitalized Patients with SARS-CoV-2 Infection
Imran Chaudhri, Farrukh M. Koraishy, Olena Bolotova, Jeanwoo Yoo, Luis A. Marcos, Erin Taub, Haseena Sahib, Michelle Bloom, Sahar Ahmad, Hal Skopicki, Sandeep K. Mallipattu
Kidney360.2020; 1(8): 801. CrossRef
Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System
Daniel L. Edmonston, Andrew M. South, Matthew A. Sparks, Jordana B. Cohen
Advances in Chronic Kidney Disease.2020; 27(5): 404. CrossRef
Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury
Riccardo Sarzani, Federico Giulietti, Chiara Di Pentima, Piero Giordano, Francesco Spannella
American Journal of Physiology-Lung Cellular and Molecular Physiology.2020; 319(2): L325. CrossRef
COVID-19 and renin-angiotensin system modulators: what do we know so far?
Angel de la Cruz, Shoaib Ashraf, Timothy J. Vittorio, Jonathan N. Bella
Expert Review of Cardiovascular Therapy.2020; 18(11): 743. CrossRef
Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis
Syed Shahzad Hasan, Chia Siang Kow, Muhammad Abdul Hadi, Syed Tabish Razi Zaidi, Hamid A. Merchant
American Journal of Cardiovascular Drugs.2020; 20(6): 571. CrossRef
Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts
Kunal Mahajan, Prakash Chand Negi, Neeraj Ganju, Sachin Sondhi, Naresh Gaur, Rao Somendra, Tomohiro Katsuya
International Journal of Hypertension.2020; 2020: 1. CrossRef
Role of Renin-Angiotensin System in Acute Lung Injury Caused by Viral Infection

Yan-Lei Gao, Yue Du, Chao Zhang, Cheng Cheng, Hai-Yan Yang, Yue-Fei Jin, Guang-Cai Duan, Shuai-Yin Chen
Infection and Drug Resistance.2020; Volume 13: 3715. CrossRef
Are losartan and imatinib effective against SARS-CoV2 pathogenesis? A pathophysiologic-based in silico study
Reza Nejat, Ahmad Shahir Sadr
In Silico Pharmacology.2020;[Epub] CrossRef
Renin–Angiotensin System: An Important Player in the Pathogenesis of Acute Respiratory Distress Syndrome
Jaroslav Hrenak, Fedor Simko
International Journal of Molecular Sciences.2020; 21(21): 8038. CrossRef
COVID-19 pandemic: a glimpse into newly diagnosed hypertensive patients
Ertan Yetkin, Gökay Taylan, Kenan Yalta
Cardiovascular Endocrinology & Metabolism.2020; 10(1): 1. CrossRef

First
Prev
Page of 1
Next
Last

Search